Literature DB >> 4449018

Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.

Y W Chien, H J Lambert, A Karim.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4449018     DOI: 10.1002/jps.2600631210

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  12 in total

1.  Altered quinidine disposition in a patient with chronic active hepatitis.

Authors:  J R Powell; R Okada; K A Conrad; T W Guentert; S Riegelman
Journal:  Postgrad Med J       Date:  1982-02       Impact factor: 2.401

2.  Plasma binding of disopyramide.

Authors:  B M David; B W Madsen; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

3.  The binding of phenylbutazone to bovine and horse serum albumin.

Authors:  M B Lambert; P P Kelly
Journal:  Ir J Med Sci       Date:  1978-06       Impact factor: 1.568

4.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

5.  Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.

Authors:  M L Aitio
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

8.  Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.

Authors:  B M David; K F Ilett; E G Whitford; N S Stenhouse
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

10.  Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.

Authors:  K Landmark; J E Bredesen; E Thaulow; S Simonsen; J P Amlie
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.